Acute Leukemia

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

CD19 Expression
CD22 Expression
Complex karyotype
HLA-A*02:01 Positive
KMT2A
KMT2A Fusion
Loss of Y
MECOM
MLF1
Monosomy 5
Monosomy 7
NPM1
NPM1 Mutation
NPM1-MLF1
NPM1-MLF1 Fusion
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3

NTRK3 Fusion
Normal karyotype
PML
PML-RARA
PML-RARA Fusion
PROM1 Expression
PROM1 Overexpression
RARA
RPN1
RPN1-MECOM

RPN1-MECOM Fusion
Trisomy 19
Trisomy 8
Very Complex karyotype
del(11)(q10)
del(12)(p10)
del(17)(p10)
del(20)(q10)
del(3)(q10)
del(5)(q10)

del(5)(q13q31)
del(5)(q22q33)
del(5)(q31q33)
del(7)(q10)
i(17)(q10)
inv(3)(q21q26)
t(12;16)(q13;p11)
t(12;21)(p13;q22)
t(12;22)(q13;q12)
t(15;17)(q22;q12)

t(15;17)(q24;q21)
t(3;3)(q21;q26)
t(3;5)(q25.1;q34)

Overview

NCI Definition: A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). [1]

Acute leukemias most frequently harbor alterations in DNMT3A, FLT3, TP53, NPM1, and RUNX1 [2].

Most Commonly Altered Genes in Acute Leukemia

DNMT3A Mutation, FLT3 Mutation, NPM1fs, TP53 Mutation, and TP53 Missense are the most common alterations in acute leukemia [2].

Top Alterations in Acute Leukemia

Clinical Trials

View Clinical Trials for Acute Leukemia

There are 27 clinical trials for acute leukemia, of which 17 are open and 10 are completed or closed. Of the trials that contain acute leukemia as an inclusion criterion, 8 are phase 1 (4 open), 8 are phase 1/phase 2 (7 open), 8 are phase 2 (5 open), 2 are phase 3 (1 open), and 1 is no phase specified (0 open).

CD19, KMT2A, and CD22 are the most frequent gene inclusion criteria for acute leukemia clinical trials [3].

Trials Investigating Acute Leukemia by Gene and Recruiting Status

Cyclophosphamide, fludarabine, and mycophenolate mofetil are the most common interventions in acute leukemia clinical trials.

Drugs Being Investigated in Acute Leukemia Trials by Recruiting Status

Significant Genes in Acute Leukemia

ABL1 +

ABL1 is altered in 0.48% of acute leukemia patients [2].

ABL1 is an inclusion eligibility criterion in 11 clinical trials for acute leukemia, of which 4 are open and 7 are closed. Of the trials that contain ABL1 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

AFF1 +

AFF1 is altered in 0.19% of acute leukemia patients [2].

AFF1 is an inclusion eligibility criterion in 9 clinical trials for acute leukemia, of which 3 are open and 6 are closed. Of the trials that contain AFF1 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

ASXL1 +

ASXL1 is altered in 13.15% of acute leukemia patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR +

BCR is altered in 0.43% of acute leukemia patients [2].

BCR is an inclusion eligibility criterion in 11 clinical trials for acute leukemia, of which 4 are open and 7 are closed. Of the trials that contain BCR status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

CBFB +

CBFB is altered in 0.5% of acute leukemia patients [2].

CBFB is an inclusion eligibility criterion in 2 clinical trials for acute leukemia, of which 0 are open and 2 are closed. Of the trials that contain CBFB status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [3].

CREBBP +

CREBBP is altered in 1.51% of acute leukemia patients [2].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain DEK status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

ELL +

ELL is altered in 1.1% of acute leukemia patients [2].

ELL is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain ELL status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

ETV6 +

ETV6 is altered in 4.33% of acute leukemia patients [2].

ETV6 is an inclusion eligibility criterion in 2 clinical trials for acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and acute leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

FLT3 +

FLT3 is altered in 15.41% of acute leukemia patients [2].

FLT3 is an inclusion eligibility criterion in 12 clinical trials for acute leukemia, of which 5 are open and 7 are closed. Of the trials that contain FLT3 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 3 are phase 1/phase 2 (3 open), 4 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

HIP1 +

HIP1 is altered in 0.37% of acute leukemia patients [2].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 +

IKZF1 is altered in 1.65% of acute leukemia patients [2].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is altered in 1.95% of acute leukemia patients [2].

KIT is an inclusion eligibility criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed. Of the trials that contain KIT status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].

KMT2A +

KMT2A is altered in 2.47% of acute leukemia patients [2].

KMT2A is an inclusion eligibility criterion in 12 clinical trials for acute leukemia, of which 6 are open and 6 are closed. Of the trials that contain KMT2A status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 4 are phase 1/phase 2 (4 open), 3 are phase 2 (2 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [3].

MECOM +

MECOM is altered in 1.36% of acute leukemia patients [2].

MECOM is an inclusion eligibility criterion in 10 clinical trials for acute leukemia, of which 5 are open and 5 are closed. Of the trials that contain MECOM status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

MLF1 +

MLF1 is an inclusion eligibility criterion in 5 clinical trials for acute leukemia, of which 3 are open and 2 are closed. Of the trials that contain MLF1 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

MLLT1 +

MLLT1 is altered in 0.68% of acute leukemia patients [2].

MLLT1 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain MLLT1 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT10 +

MLLT10 is altered in 0.68% of acute leukemia patients [2].

MLLT10 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain MLLT10 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT3 +

MLLT3 is altered in 1.01% of acute leukemia patients [2].

MLLT3 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain MLLT3 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MLLT4 +

MLLT4 is altered in 0.73% of acute leukemia patients [2].

MLLT4 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain MLLT4 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MYH11 +

MYH11 is altered in 0.2% of acute leukemia patients [2].

MYH11 is an inclusion eligibility criterion in 2 clinical trials for acute leukemia, of which 0 are open and 2 are closed. Of the trials that contain MYH11 status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [3].

NPM1 +

NPM1 is altered in 14.14% of acute leukemia patients [2].

NPM1 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 5 are open and 2 are closed. Of the trials that contain NPM1 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].

NRIP3 +

NRIP3 is altered in 0.73% of acute leukemia patients [2].

NRIP3 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain NRIP3 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

NTRK1 +

NTRK1 is altered in 0.5% of acute leukemia patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 +

NTRK2 is altered in 0.08% of acute leukemia patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 +

NTRK3 is altered in 0.25% of acute leukemia patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain NUP214 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 4 are open and 3 are closed. Of the trials that contain PBX1 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

PDGFRB +

PDGFRB is altered in 0.67% of acute leukemia patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PRDM16 +

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 10 clinical trials for acute leukemia, of which 5 are open and 5 are closed. Of the trials that contain RPN1 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

RUNX1 +

RUNX1 is altered in 14.81% of acute leukemia patients [2].

RUNX1 is an inclusion eligibility criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed. Of the trials that contain RUNX1 status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [3].

RUNX1T1 +

RUNX1T1 is altered in 1.39% of acute leukemia patients [2].

RUNX1T1 is an inclusion eligibility criterion in 2 clinical trials for acute leukemia, of which 0 are open and 2 are closed. Of the trials that contain RUNX1T1 status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [3].

TCF3 +

TCF3 is altered in 0.52% of acute leukemia patients [2].

TCF3 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 4 are open and 3 are closed. Of the trials that contain TCF3 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [3].

TP53 +

TP53 is altered in 14.85% of acute leukemia patients [2].

TP53 is an inclusion eligibility criterion in 7 clinical trials for acute leukemia, of which 2 are open and 5 are closed. Of the trials that contain TP53 status and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

Disease Details

Synonyms

Bone marrow leukemia acute, PEDIATRIC Bone marrow leukemia acute

Parent(s)

Leukemia

Children

Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage, and Acute Myeloid Leukemia

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Acute Leukemia

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Acute Leukemia

Disease Details

References

About

Molecular Medicine

Content Types